(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

Wall Street shares last night weakened, with the S&P 500 index down 0.3% ahead of tonight’s interest rate decision and latest batch of megacap earnings. The Dow Jones Industrial Average also fell 0.5% ...

British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

GSK boasts an average earnings surprise of 8.6%. With a solid Zacks Rank and top-tier Growth and VGM Style Scores, GSK should be on investors' short list.

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also ...